Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)
NCT00546572 · View on ClinicalTrials.gov ↗
Study Summary
This study will evaluate the safety, tolerability and immunogenicity of study vaccines 13vPnC and 23vPS in older, healthy subjects who have previously received a dose of 23vPS at least 5 years ago. It will also evaluate the safety, tolerability and immunogenicity to a dose of 13vPnC 1 year after the initial dose of study vaccine.
Conditions Studied
Interventions
- BIOLOGICAL 13 valent Pneumococcal Conjugate Vaccine
- BIOLOGICAL 23vPS
Study Locations (20)
Florida
- Pfizer Investigational Site — Clearwater
- Pfizer Investigational Site — Coral Gables
- Pfizer Investigational Site — Jacksonville
- Pfizer Investigational Site — Pinellas Park
- Pfizer Investigational Site — Tampa
Georgia
- Pfizer Investigational Site — Atlanta
- Pfizer Investigational Site — Atlanta
- Pfizer Investigational Site — Stockbridge
Arizona
- Pfizer Investigational Site — Mesa
- Pfizer Investigational Site — Mesa
Minnesota
- Pfizer Investigational Site — Minneapolis
- Pfizer Investigational Site — Rochester
Alabama
- Pfizer Investigational Site — Mobile
California
- Pfizer Investigational Site — Fountain Valley
Colorado
- Pfizer Investigational Site — Denver
Connecticut
- Pfizer Investigational Site — Waterbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 938 participants |
| Start Date | 2007-11 |
| Est. Completion | 2010-07 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00546572
The ClinicalTrials.gov registry entry for NCT00546572 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 938 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 31 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Pneumococcal Infections appearing as the primary indexed condition, and to 2 interventions — of which 13 valent Pneumococcal Conjugate Vaccine is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00546572 reports 20 study locations spanning 12 distinct geographic areas — top geographies include Florida, Georgia, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00546572 about?
NCT00546572 is a clinical study titled "Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)". This study will evaluate the safety, tolerability and immunogenicity of study vaccines 13vPnC and 23vPS in older, healthy subjects who have previously received a dose of 23vPS at least 5 years ago. It will also evaluate the safety, tolerability and immunogenicity to a dose of 13vPnC 1 year after the...
What is the current status of trial NCT00546572?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 938 participants. The study started on 2007-11. Estimated completion is 2010-07.
What conditions does trial NCT00546572 study?
This clinical trial studies the following conditions: Pneumococcal Infections. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00546572?
The interventions under investigation include: 13 valent Pneumococcal Conjugate Vaccine (BIOLOGICAL), 23vPS (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00546572?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 31 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00546572 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.